autoimmune disease

A new approach for gene editing will get its shot in a common and chronic autoimmune disorder.

As a CD40 ligand antagonist, dazodalibep blocks immune cell communication, potentially serving as the first drug to target the autoimmune disease’s cause.

Industry leaders name the clinical trials and developments they’re most excited to see in the new year.

Bristol Myers Squibb unveiled promising CAR T cell therapy data for severe autoimmune diseases from their Phase 1 clinical trial, offering hope for remission.

Novartis’ iscalimab may improve troubling symptoms in patients with Sjögren’s disease, though there may be safety concerns to address.

Exhilarated but cautious, researchers are eager to see if CAR T cell therapy offers a one-time treatment for lupus.

A changing dance of transcription factors modulates T regulatory cell gene expression in different immune contexts with implications for cancer and autoimmune diseases.

Scientists discover an ultra-rare monoclonal antibody directly from patients with autoimmune diseases.

Once symptoms show up, it’s too late to cure many autoimmune diseases. Researchers are investigating ways to prevent the conditions from starting at all.

Genetically modified stem cells show promise in a targeted approach to taming inflammation in autoimmune diseases.